Chin-Fu Hsiao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7795954/publications.pdf

Version: 2024-02-01

147 147 147 6419
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Three-Stage Pooled Plasma Hepatitis C Virus RNA Testing for the Identification of Acute HCV Infections in At-Risk Populations. Microbiology Spectrum, 2022, 10, e0243721.	3.0	11
2	On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes. Contemporary Clinical Trials, 2021, 101, 106244.	1.8	O
3	Use of a twoâ€sided tolerance interval in the design and evaluation of biosimilarity in clinical studies. Pharmaceutical Statistics, 2021, 20, 175-184.	1.3	2
4	Sub-multiplicative interaction between polygenic risk score and household coal use in relation to lung adenocarcinoma among never-smoking women in Asia. Environment International, 2021, 147, 105975.	10.0	12
5	Tolerance interval testing for assessing accuracy and precision simultaneously. PLoS ONE, 2021, 16, e0246642.	2.5	2
6	A phase 2 study of liposomal irinotecan with 5-fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy Journal of Clinical Oncology, 2021, 39, 6025-6025.	1.6	2
7	High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial. Radiotherapy and Oncology, 2021, 158, 146-154.	0.6	7
8	TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma Journal of Clinical Oncology, 2021, 39, 4143-4143.	1.6	6
9	Use of likelihood estimates for variances for the design and evaluation of multiregional clinical trials with heterogeneous variances. Statistics in Medicine, 2021, , .	1.6	O
10	The Prognostic and Predictive Role of Chromogranin A in Gastroenteropancreatic Neuroendocrine Tumors $\hat{a} \in A$ Single-Center Experience. Frontiers in Oncology, 2021, 11, 741096.	2.8	9
11	Predicting Lung Cancer Occurrence in Never-Smoking Females in Asia: TNSF-SQ, a Prediction Model. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 452-459.	2.5	31
12	Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection. Journal of the Formosan Medical Association, 2020, 119, 335-344.	1.7	8
13	Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women. Genomics, 2020, 112, 1223-1232.	2.9	15
14	A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma–TCOG T1211 study. European Journal of Cancer, 2020, 124, 123-130.	2.8	11
15	Use of tolerance intervals for assessing biosimilarity. Statistics in Medicine, 2020, 39, 3806-3822.	1.6	1
16	Operational Experiences in China and Statistical Issues on the Conduct of Clinical Trials During the COVID-19 Pandemic. Statistics in Biopharmaceutical Research, 2020, 12, 438-442.	0.8	2
17	A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue. Haematologica, 2020, 105, e349-e354.	3.5	5
18	Impact of cooking oil fume exposure and fume extractor use on lung cancer risk in non-smoking Han Chinese women. Scientific Reports, 2020, 10, 6774.	3.3	41

#	Article	IF	Citations
19	Use of a tolerance interval approach as a statistical quality control tool for traditional Chinese medicine. Journal of Biopharmaceutical Statistics, 2020, 30, 873-881.	0.8	1
20	An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas. Oncologist, 2020, 25, e782-e788.	3.7	7
21	A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). PLoS ONE, 2020, 15, e0242763.	2.5	65
22	Title is missing!. , 2020, 15, e0242763.		O
23	Title is missing!. , 2020, 15, e0242763.		0
24	Title is missing!. , 2020, 15, e0242763.		0
25	Title is missing!. , 2020, 15, e0242763.		O
26	Use of interval estimations in design and evaluation of multiregional clinical trials with continuous outcomes. Statistical Methods in Medical Research, 2019, 28, 2179-2195.	1.5	3
27	An open label, single-arm, two-stage, multicenter, phase II study to evaluate the efficacy and safety of TLC388 as second-line treatment in subjects with poorly differentiated neuroendocrine carcinomas (TCOGT1Z14) Journal of Clinical Oncology, 2019, 37, 4101-4101.	1.6	1
28	Use of a Bayesian approach in the design and evaluation of NCE2s. Journal of Food and Drug Analysis, 2018, 26, 416-421.	1.9	0
29	Design and Data Analysis of Multiregional Clinical Trials (MRCTs)—Theory and Practice. ICSA Book Series in Statistics, 2018, , 269-286.	0.2	O
30	Differences in healthâ€related quality of life between European and Asian patients with hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e304-e311.	1.1	9
31	An approach for sample size determination of average bioequivalence based on interval estimation. Statistics in Medicine, 2017, 36, 1068-1082.	1.6	1
32	A Tolerance Interval Approach to Assessing the Biosimilarity of Follow-On Biologics. Statistics in Biopharmaceutical Research, 2017, 9, 286-292.	0.8	2
33	Intake of potassium- and magnesium-enriched salt improves functional outcome after stroke: a randomized, multicenter, double-blind controlled trial. American Journal of Clinical Nutrition, 2017, 106, 1267-1273.	4.7	25
34	Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy. Scientific Reports, 2017, 7, 16187.	3.3	8
35	Integrated care for geriatric frailty and sarcopenia: a randomized control trial. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 78-88.	7.3	56
36	Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 663-673.	5.6	24

#	Article	IF	CITATIONS
37	Sample size determination for a specific region in multiregional clinical trials with multiple co-primary endpoints. PLoS ONE, 2017, 12, e0180405.	2.5	1
38	Assessing the consistency of the treatment effect under the discrete random effects model in multiregional clinical trials. Statistics in Medicine, 2016, 35, 2301-2314.	1.6	12
39	Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations. Human Molecular Genetics, 2016, 26, ddw414.	2.9	50
40	A Phase II Study of Sequential Capecitabine Plus Oxaliplatin Followed by Docetaxel Plus Capecitabine in Patients With Unresectable Gastric Adenocarcinoma. Medicine (United States), 2016, 95, e2565.	1.0	0
41	Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. Human Molecular Genetics, 2016, 25, 620-629.	2.9	50
42	Assessing Benefit and Consistency of Treatment Effect Under a Discrete Random Effects Model in Multiregional Clinical Trials. ICSA Book Series in Statistics, 2016, , 127-136.	0.2	0
43	Estrogen Receptor Gene Polymorphisms and Lung Adenocarcinoma Risk in Never-Smoking Women. Journal of Thoracic Oncology, 2015, 10, 1413-1420.	1.1	17
44	<scp>G</scp> enetic variants associated with longer telomere length are associated with increased lung cancer risk among neverâ∈smoking women in Asia: a report from the female lung cancer consortium in Asia. International Journal of Cancer, 2015, 137, 311-319.	5.1	72
45	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. Journal of the National Cancer Institute, 2015, 107, djv279.	6.3	152
46	Interactions between household air pollution and GWAS-identified lung cancer susceptibility markers in the Female Lung Cancer Consortium in Asia (FLCCA). Human Genetics, 2015, 134, 333-341.	3.8	34
47	Chemokine IP-10 is correlated with cardiac responses and status of infection with HIV and HCV in methadone maintenance patients. International Journal of Cardiology, 2015, 194, 36-38.	1.7	3
48	Quality of life changes in patients undergoing treatment for hepatocellular carcinoma. Quality of Life Research, 2015, 24, 2499-2506.	3.1	26
49	Sample Size Determination for Individual Bioequivalence Inference. PLoS ONE, 2014, 9, e109746.	2.5	2
50	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
51	Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: A phase II TCOG study. Journal of Surgical Oncology, 2014, 109, 580-585.	1.7	21
52	Sample size determination for within-device precision. Journal of Chemometrics, 2014, 28, 202-211.	1.3	1
53	The Association of Genetic Polymorphisms in the \hat{I}^2 -Opioid Receptor 1 Gene With Body Weight, Alcohol Use, and Withdrawal Symptoms in Patients With Methadone Maintenance. Journal of Clinical Psychopharmacology, 2014, 34, 205-211.	1.4	29
54	Sample Size Estimation of Multiregional Clinical Trials with Heterogeneous Variability Across Regions. Journal of Biopharmaceutical Statistics, 2014, 24, 254-271.	0.8	5

#	Article	lF	CITATIONS
55	Insulin Resistance: Regression and Clustering. PLoS ONE, 2014, 9, e94129.	2.5	2
56	OPRM1 genetic polymorphisms are associated with the plasma nicotine metabolite cotinine concentration in methadone maintenance patients: a cross sectional study. Journal of Human Genetics, 2013, 58, 84-90.	2.3	27
57	<i>CYP1A2</i> genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions. Pharmacogenomics, 2013, 14, 1191-1201.	1.3	25
58	An empirical Bayes approach to evaluation of results for a specific region in multiregional clinical trials. Pharmaceutical Statistics, 2013, 12, 59-64.	1.3	6
59	Risk factors for primary lung cancer among never smokers by gender in a matched case–control study. Cancer Causes and Control, 2013, 24, 567-576.	1.8	51
60	Endothelin Type A Receptor Genotype is a Determinant of Quantitative Traits of Metabolic Syndrome in Asian Hypertensive Families: A SAPPHIRe Study. Frontiers in Endocrinology, 2013, 4, 172.	3.5	3
61	Comparison of escitalopram and paroxetine in the treatment of major depressive disorder. International Clinical Psychopharmacology, 2013, 28, 339-345.	1.7	6
62	EGFR polymorphisms, hormone replacement therapy and lung adenocarcinoma risk: analysis from a genome-wide association study in never-smoking women. Carcinogenesis, 2013, 34, 612-619.	2.8	15
63	Functional Genetic Polymorphisms in <i>CYP2C19</i> Gene in Relation to Cardiac Side Effects and Treatment Dose in a Methadone Maintenance Cohort. OMICS A Journal of Integrative Biology, 2013, 17, 519-526.	2.0	35
64	PXR Polymorphisms Interacted With CYP2B6 Polymorphisms on Methadone Metabolites. Journal of Clinical Psychopharmacology, 2013, 33, 137-140.	1.4	6
65	Use of Random Effect Models in the Design and Analysis of Multi-regional Clinical Trials. Springer Proceedings in Mathematics and Statistics, 2013, , 325-334.	0.2	0
66	Design and Analysis Issues of Multiregional Clinical Trials with Different Regional Primary Endpoints. Journal of Biopharmaceutical Statistics, 2012, 22, 1051-1059.	0.8	5
67	Design and Evaluation of Multiregional Trials with Heterogeneous Treatment Effect Across Regions. Journal of Biopharmaceutical Statistics, 2012, 22, 1037-1050.	0.8	15
68	The effects of the renin-angiotensin-aldosterone system gene polymorphisms on insulin resistance in hypertensive families. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 446-454.	1.7	11
69	Long-Term Results of a Randomized, Observation-Controlled, Phase III Trial of Adjuvant Interferon Alfa-2b in Hepatocellular Carcinoma After Curative Resection. Annals of Surgery, 2012, 255, 8-17.	4.2	111
70	Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nature Genetics, 2012, 44, 1330-1335.	21.4	286
71	Genetic polymorphisms in the opioid receptor mu1 gene are associated with changes in libido and insomnia in methadone maintenance patients. European Neuropsychopharmacology, 2012, 22, 695-703.	0.7	52
72	Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients. Vaccine, 2012, 30, 3526-3533.	3.8	10

#	Article	IF	Citations
73	Statistical Methods for Bridging Studies. Journal of Biopharmaceutical Statistics, 2012, 22, 903-915.	0.8	9
74	Establishing consistency across all regions in a multiâ€regional clinical trial. Pharmaceutical Statistics, 2012, 11, 295-299.	1.3	21
75	International cross-cultural field validation of an European Organization for Research and Treatment of Cancer questionnaire module for patients with primary liver cancer, the European Organization for Research and Treatment of Cancer quality-of-life ques. Hepatology, 2012, 55, 1122-1129.	7. 3	37
76	<i>UGT2B7</i> genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients. Pharmacogenomics, 2012, 13, 879-888.	1.3	31
77	Genetic variant in TP63 on locus 3q28 is associated with risk of lung adenocarcinoma among never-smoking females in Asia. Human Genetics, 2012, 131, 1197-1203.	3.8	39
78	Bridging Diversity. Chapman & Hall/CRC Biostatistics Series, 2012, , 1-16.	0.0	0
79	Polymorphisms of MLH1 and MSH2 genes and the risk of lung cancer among never smokers. Lung Cancer, 2011, 72, 280-286.	2.0	48
80	CYP2B6 Polymorphisms Influence the Plasma Concentration and Clearance of the Methadone S-Enantiomer. Journal of Clinical Psychopharmacology, 2011, 31, 463-469.	1.4	68
81	A consistency approach to evaluation of bridging studies and multi-regional trials. Statistics in Medicine, 2011, 30, 2171-2186.	1.6	13
82	An alternative phase II/III design for continuous endpoints. Pharmaceutical Statistics, 2011, 10, 105-114.	1.3	5
83	Genetic polymorphisms in <i>CYP3A4</i> are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients. Pharmacogenomics, 2011, 12, 1397-1406.	1.3	57
84	Proposals of statistical consideration to evaluation of results for a specific region in multiâ€regional trials – Asian perspective. Pharmaceutical Statistics, 2010, 9, 201-206.	1.3	20
85	Sample Size Determination for a Specific Region in a Multiregional Trial. Journal of Biopharmaceutical Statistics, 2010, 20, 870-885.	0.8	48
86	The 5p15.33 Locus Is Associated with Risk of Lung Adenocarcinoma in Never-Smoking Females in Asia. PLoS Genetics, 2010, 6, e1001051.	3.5	168
87	ATM polymorphisms and risk of lung cancer among never smokers. Lung Cancer, 2010, 69, 148-154.	2.0	45
88	Genetic variants of human urea transporter-2 are associated with metabolic syndrome in Asian population. Clinica Chimica Acta, 2010, 411, 2009-2013.	1.1	10
89	<i>CYP1A2</i> genetic polymorphisms are associated with treatment response to the antidepressant paroxetine. Pharmacogenomics, 2010, 11, 1535-1543.	1.3	37
90	Bridging Diversity. Pharmaceutical Medicine, 2010, 24, 349-362.	1.9	8

#	Article	IF	CITATIONS
91	Statistical Test for Evaluation of Biosimilarity in Variability of Follow-On Biologics. Journal of Biopharmaceutical Statistics, 2009, 20, 75-89.	0.8	13
92	Interactive Effect of Cigarette Smoking With Human 8-Oxoguanine DNA N-Glycosylase 1 (hOGG1) Polymorphisms on the Risk of Lung Cancer: A Case-Control Study in Taiwan. American Journal of Epidemiology, 2009, 170, 695-702.	3.4	53
93	Statistical Validation of Traditional Chinese Diagnostic Procedures. Drug Information Journal, 2009, 43, 83-95.	0.5	3
94	A Polymorphism in the <i>APE1</i> Gene Promoter is Associated with Lung Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 223-229.	2.5	75
95	Non-lethal Candida albicans cph1/cph1 efg1/efg1 mutant partially protects mice from systemic infections by lethal wild-type cells. Mycological Research, 2009, 113, 388-390.	2.5	9
96	Statistical methods for evaluating the linearity in assay validation. Journal of Chemometrics, 2009, 23, 56-63.	1.3	9
97	Association of an EGFR intron 1 SNP with never-smoking female lung adenocarcinoma patients. Lung Cancer, 2009, 64, 251-256.	2.0	34
98	Medical resource utilizations and economic burden in Chinese cancer patients with chemotherapy-induced anemia: A populational database study. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2008, 20, 307-315.	2.2	1
99	Translation in Different Diagnostic Procedures—Traditional Chinese Medicine and Western Medicine. Journal of the Formosan Medical Association, 2008, 107, S74-S85.	1.7	5
100	A Two-Stage Design for Drug Screening Trials Based on Continuous Endpoints. Drug Information Journal, 2008, 42, 253-262.	0.5	5
101	Methicillin-resistant Staphylococcus aureus carriage, infection and transmission in dialysis patients, healthcare workers and their family members. Nephrology Dialysis Transplantation, 2008, 23, 1659-1665.	0.7	77
102	Increased Risk for Entamoeba histolytica Infection and Invasive Amebiasis in HIV Seropositive Men Who Have Sex with Men in Taiwan. PLoS Neglected Tropical Diseases, 2008, 2, e175.	3.0	79
103	Translation in Clinical Information between Populations—Bridging Studies. Chapman & Hall/CRC Biostatistics Series, 2008, , .	0.0	0
104	Translation in Clinical Technology—Traditional Chinese Medicine. Chapman & Hall/CRC Biostatistics Series, 2008, , .	0.0	0
105	Mixed Noninferiority Margin and Statistical Tests in Active Controlled Trials. Journal of Biopharmaceutical Statistics, 2007, 17, 339-357.	0.8	8
106	Use of Prior Information for Bayesian Evaluation of Bridging Studies. Journal of Biopharmaceutical Statistics, 2007, 17, 109-121.	0.8	30
107	Clonality and Prognostic Implications of p53 and Epidermal Growth Factor Receptor Somatic Aberrations in Multiple Primary Lung Cancers. Clinical Cancer Research, 2007, 13, 52-58.	7.0	98
108	Risk of Recurrent Nontyphoid Salmonella Bacteremia in HIV-Infected Patients in the Era of Highly Active Antiretroviral Therapy and an Increasing Trend of Fluoroquinolone Resistance. Clinical Infectious Diseases, 2007, 45, e60-e67.	5 . 8	48

#	Article	IF	Citations
109	Comprehensive linkage and linkage heterogeneity analysis of 4344 sibling pairs affected with hypertension from the Family Blood Pressure Program. Genetic Epidemiology, 2007, 31, 195-210.	1.3	6
110	Hormone replacement therapy and lung cancer risk in Chinese. Cancer, 2007, 110, 1768-1775.	4.1	53
111	Bayes optimal sequential trial designs. Journal of Statistical Planning and Inference, 2007, 137, 1129-1137.	0.6	2
112	Genome-Wide Linkage Analysis of Lipids in Nondiabetic Chinese and Japanese From the SAPPHIRe Family Study. American Journal of Hypertension, 2006, 19, 1270-1277.	2.0	8
113	The insulin sensitivity, glucose sensitivity, and acute insulin response to glucose load in adolescent type 2 diabetes in Taiwanese. Diabetes/Metabolism Research and Reviews, 2006, 22, 26-33.	4.0	10
114	HIGHER SEROPREVALENCE OF ENTAMOEBA HISTOLYTICA INFECTION IS ASSOCIATED WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION IN TAIWAN. American Journal of Tropical Medicine and Hygiene, 2006, 74, 1016-1019.	1.4	36
115	Higher seroprevalence of Entamoeba histolytica infection is associated with human immunodeficiency virus type 1 infection in Taiwan. American Journal of Tropical Medicine and Hygiene, 2006, 74, 1016-9.	1.4	18
116	Changes in the clinical spectrum of opportunistic illnesses in persons with HIV infection in Taiwan in the era of highly active antiretroviral therapy. Japanese Journal of Infectious Diseases, 2006, 59, 311-6.	1.2	26
117	Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer. International Journal of Cancer, 2005, 117, 241-247.	5.1	84
118	Evaluation of Experimental Designs for Two-Color cDNA Microarrays. Journal of Computational Biology, 2005, 12, 1202-1220.	1.6	5
119	An Autosomal Genome-wide Scan for Loci Linked to Pre-Diabetic Phenotypes in Nondiabetic Chinese Subjects From the Stanford Asia-Pacific Program of Hypertension and Insulin Resistance Family Study. Diabetes, 2005, 54, 1200-1206.	0.6	29
120	Invasive Amebiasis as an Emerging Parasitic Disease in Patients With Human Immunodeficiency Virus Type 1 Infection in Taiwan. Archives of Internal Medicine, 2005, 165, 409.	3.8	91
121	Colonization of Human Immunodeficiency Virus-Infected Outpatients in Taiwan with Candida Species. Journal of Clinical Microbiology, 2005, 43, 1600-1603.	3.9	50
122	Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respiratory Medicine, 2005, 99, 1079-1086.	2.9	87
123	Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study. International Journal of STD and AIDS, 2005, 16, 673-676.	1.1	31
124	Impact of Chronic Hepatitis B Virus (HBV) Infection on Outcomes of Patients Infected with HIV in an Area Where HBV Infection Is Hyperendemic. Clinical Infectious Diseases, 2004, 38, 1471-1477.	5.8	78
125	Clustering of Minimal Deleted Regions Reveals Distinct Genetic Pathways of Human Hepatocellular Carcinoma. Cancer Research, 2004, 64, 3030-3036.	0.9	38
126	Physical Inactivity is an Important Lifestyle Determinant of Insulin Resistance in Hypertensive Patients. Blood Pressure, 2004, 13, 355-361.	1.5	24

#	Article	IF	CITATIONS
127	A Bayesian Noninferiority Approach to Evaluation of Bridging Studies. Journal of Biopharmaceutical Statistics, 2004, 14, 291-300.	0.8	16
128	A TWO-STAGE DESIGN FOR BRIDGING STUDIES. Journal of Biopharmaceutical Statistics, 2004, 15, 75-83.	0.8	21
129	The insulin sensitivity, glucose effectiveness and acute insulin response to glucose load of non-obese adolescent type 2 diabetes. Diabetes Research and Clinical Practice, 2004, 66, 253-261.	2.8	5
130	Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study. Vaccine, 2004, 22, 2006-2012.	3.8	58
131	Correlation Between Bone Mineral Density and Plasma Lipids in Taiwan. Endocrine Research, 2003, 29, 317-325.	1.2	54
132	Isolated Antibody to Hepatitis B Core Antigen in Individuals Infected with HIV-1. Clinical Infectious Diseases, 2003, 37, 1275-1276.	5.8	12
133	A Group Sequential Approach to Evaluation of Bridging Studies. Journal of Biopharmaceutical Statistics, 2003, 13, 793-801.	0.8	18
134	Waist circumference predicts metabolic cardiovascular risk in postmenopausal Chinese women. Menopause, 2003, 10, 73-80.	2.0	11
135	Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. Aids, 2003, 17, 2615-2622.	2.2	54
136	Recurrence of Tuberculosis in HIV-1–Infected Adults Treated After Rifamycin-Based Treatment and Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 437-439.	2.1	2
137	Fluconazole resistance rate of Candida species from different regions and hospital types in Taiwan. Journal of Microbiology, Immunology and Infection, 2003, 36, 187-91.	3.1	32
138	BAYESIAN APPROACH TO EVALUATION OF BRIDGING STUDIES. Journal of Biopharmaceutical Statistics, 2002, 12, 401-408.	0.8	34
139	Definition of three minimal deleted regions by comprehensive allelotyping and mutational screening of FHIT,p16INK4A, and p19ARF genes in nasopharyngeal carcinoma. Cancer, 2002, 94, 1987-1996.	4.1	20
140	Discontinuation of secondary prophylaxis for penicilliosis marneffei in AIDS patients responding to highly active antiretroviral therapy. Aids, 2002, 16, 672-673.	2.2	20
141	Clustering and Heritability of Insulin Resistance in Chinese and Japanese Hypertensive Families: A Stanford-Asian Pacific Program in Hypertension and Insulin Resistance Sibling Study Hypertension Research, 2002, 25, 529-536.	2.7	45
142	BAYES DISCRETE SEQUENTIAL BOUNDARIES FOR CLINICAL TRIALS. Communications in Statistics - Theory and Methods, 2001, 30, 1381-1394.	1.0	2
143	LERCHE'S SEQUENTIAL TEST FOR THE DRIFT OF A BROWNIAN MOTION WITH A SMOOTH PRIOR. Sequential Analysis, 2001, 20, 183-199.	0.5	0
144	Risk of recurrent non-typhoid Salmonella bacteraemia after early discontinuation of ciprofloxacin as secondary prophylaxis in AIDS patients in the era of highly active antiretroviral therapy. Aids, 2001, 15, 645-647.	2.2	16

#	Article	IF	CITATIONS
145	Comment on "Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment― Is Real-World Evidence Real?. Statistics in Biopharmaceutical Research, 0, , 1-2.	0.8	2